29 Results

• You have access

  Plasma and Liver Protein Binding of N-Acetylgalactosamine–Conjugated Small Interfering RNA

  Sara C. Humphreys, Mai B. Thayer, Julie M. Lade, Bin Wu, Kelvin Sham, Babak Basiri, Yue Hao, Xin Huang, Richard Smith and Brooke M. Rock

  Drug Metabolism and Disposition October 2019, 47 (10) 1174-1182; DOI: https://doi.org/10.1124/dmd.119.086967
• You have access

  Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity

  Rachel J. Eclov, Mee J. Kim, Robin Smith, Nadav Ahituv and Deanna L. Kroetz

  Drug Metabolism and Disposition May 2018, 46 (5) 636-642; DOI: https://doi.org/10.1124/dmd.117.079541
• You have access

  In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus

  Rachel J. Eclov, Mee J. Kim, Robin P. Smith, Xiaomin Liang, Nadav Ahituv and Deanna L. Kroetz

  Drug Metabolism and Disposition February 2017, 45 (2) 208-215; DOI: https://doi.org/10.1124/dmd.116.072033
• You have access

  Inflammation-Induced Phenoconversion of Polymorphic Drug Metabolizing Enzymes: Hypothesis with Implications for Personalized Medicine

  Rashmi R. Shah and Robert L. Smith

  Drug Metabolism and Disposition March 2015, 43 (3) 400-410; DOI: https://doi.org/10.1124/dmd.114.061093
• You have access

  An In Vitro Assay to Assess Transporter-Based Cholestatic Hepatotoxicity Using Sandwich-Cultured Rat Hepatocytes

  John H. Ansede, William R. Smith, Cassandra H. Perry, Robert L. St. Claire and Kenneth R. Brouwer

  Drug Metabolism and Disposition February 2010, 38 (2) 276-280; DOI: https://doi.org/10.1124/dmd.109.028407
• You have access

  The Disposition of Prasugrel, a Novel Thienopyridine, in Humans

  Nagy A. Farid, Richard L. Smith, Todd A. Gillespie, T. James Rash, Patrick E. Blair, Atsushi Kurihara and Mark J. Goldberg

  Drug Metabolism and Disposition July 2007, 35 (7) 1096-1104; DOI: https://doi.org/10.1124/dmd.106.014522
• You have access

  A COMPREHENSIVE QUANTITATIVE AND QUALITATIVE EVALUATION OF EXTRAPOLATION OF INTRAVENOUS PHARMACOKINETIC PARAMETERS FROM RAT, DOG, AND MONKEY TO HUMANS. I. CLEARANCE

  Keith W. Ward and Brian R. Smith

  Drug Metabolism and Disposition June 2004, 32 (6) 603-611; DOI: https://doi.org/10.1124/dmd.32.6.603
• You have access

  A COMPREHENSIVE QUANTITATIVE AND QUALITATIVE EVALUATION OF EXTRAPOLATION OF INTRAVENOUS PHARMACOKINETIC PARAMETERS FROM RAT, DOG, AND MONKEY TO HUMANS. II. VOLUME OF DISTRIBUTION AND MEAN RESIDENCE TIME

  Keith W. Ward and Brian R. Smith

  Drug Metabolism and Disposition June 2004, 32 (6) 612-619; DOI: https://doi.org/10.1124/dmd.32.6.612
• You have access

  DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

  Keith W. Ward, Gary J. Stelman, Jayme A. Morgan, Kelli S. Zeigler, Leonard M. Azzarano, Jonathan R. Kehler, Jeanelle E. McSurdy-Freed, Joel W. Proksch and Brian R. Smith

  Drug Metabolism and Disposition February 2004, 32 (2) 172-177; DOI: https://doi.org/10.1124/dmd.32.2.172
• You have access

  Trimethylaminuria: The Fish Malodor Syndrome

  S. C. Mitchell and R. L. Smith

  Drug Metabolism and Disposition April 2001, 29 (4) 517-521;

Pages